RETIN-A MICRO® (tretinoin gel) microsphere, 0.04%/0.1% Pump in Both 0.04% and 0.1% Concentrations Delivered Significant Improvement in Acne Severity at 12 Weeks*1

Chart: RETIN-A MICRO Pump in Both 0.04% and 0.1% Concentrations Delivered Significant Improvement in Acne Severity at 12 Weeks

Pivotal trials validate: RETIN-A MICRO® reduces both inflammatory and noninflammatory lesions†2

Chart: Pivotal trials validate: RETIN-A MICRO reduces both inflammatory and noninflammatory lesions

RETIN-A MICRO® Pump delivers the efficacy that patients want—so they stay on therapy* 1,3

* Investigator’s global evaluation (IGE) of treatment response at week 12 using signed-rank tests for individual treatments. Improvement in the IGE at week 12 was statistically significant for both 0.04% and 0.1% strengths (p=0.0001).
† Combined analysis of two pivotal vehicle-controlled trials evaluating the safety and efficacy of RETIN-A MICRO® (tretinoin gel) microsphere, 0.04% in the treatment of acne vulgaris (N=199).
References:
1.Eichenfield LF, Nighland M, Rossi AB, et al; PUMP Study Group. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129–1136.
2.Data on file, Ortho Dermatologics.
3.Bergfeld WF. Optimizing the approach to acne therapy. Cosmet Dermatol. 1999;12(4):26–37.